List of Excipients in Branded Drug FLEQSUVY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	FLEQSUVY	baclofen	52652-6001	ANHYDROUS CITRIC ACID
Azurity Pharmaceuticals Inc	FLEQSUVY	baclofen	52652-6001	D&C YELLOW NO. 10
Azurity Pharmaceuticals Inc	FLEQSUVY	baclofen	52652-6001	DIMETHICONE
Azurity Pharmaceuticals Inc	FLEQSUVY	baclofen	52652-6001	FD&C RED NO. 40
Azurity Pharmaceuticals Inc	FLEQSUVY	baclofen	52652-6001	HYDROXYETHYL CELLULOSE

Fleqsuvy Excipient Strategy and Commercial Opportunities: Baclofen Oral Suspension Patent, Regulatory and Market Analysis

Last updated: August 9, 2026

Fleqsuvy is a ready-to-use baclofen oral suspension developed by Azurity Pharmaceuticals for spasticity. Its commercial differentiation comes from liquid delivery, a higher concentration of 25 mg per 5 mL, dosing flexibility, and suitability for patients who cannot swallow tablets. The active ingredient, baclofen, is generic and has limited exclusivity value. The main defensible opportunities are formulation know-how, taste masking, physical stability, dosing accuracy, packaging, and specialty distribution.

What is Fleqsuvy and how does its formulation differ from baclofen tablets?

Fleqsuvy contains baclofen, a gamma-aminobutyric acid-B receptor agonist used to treat spasticity associated with multiple sclerosis, spinal cord disease, and other neurologic disorders. The product is an oral suspension supplied at 25 mg per 5 mL, equivalent to 5 mg/mL.[1]

The higher concentration reduces administration volume relative with lower-strength baclofen liquids. A 20 mg dose requires 4 mL of Fleqsuvy, compared with 20 mL of a 5 mg/5 mL solution. This is commercially relevant for adults receiving multiple daily doses and for patients using enteral feeding tubes.

Product	Active ingredient	Strength	Dosage form	Primary commercial distinction
Fleqsuvy	Baclofen	25 mg/5 mL	Oral suspension	High-concentration liquid
Ozobax	Baclofen	5 mg/5 mL	Oral solution	Ready-to-use low-concentration liquid
Generic baclofen tablets	Baclofen	Commonly 5 mg and 10 mg	Tablet	Low-cost solid dosage form
Compounded baclofen liquid	Baclofen	Variable	Extemporaneous liquid	Custom strength, variable access and consistency

Fleqsuvy is intended for patients who have difficulty swallowing tablets or require individualized liquid dosing. Its suspension format creates formulation and administration requirements that do not apply to conventional tablets.

What excipients are used in Fleqsuvy?

Fleqsuvy uses a conventional aqueous suspension system with viscosity control, sweetening, buffering, preservation, and flavoring components. The FDA label identifies the following inactive ingredients:

Excipient	Likely formulation role
Glycerin	Humectant, solvent, mouthfeel modifier, sweetness contributor
Microcrystalline cellulose and carboxymethylcellulose sodium	Suspending and rheology system
Sucralose	High-intensity sweetener
Sodium citrate dihydrate	Buffering and pH control
Citric acid monohydrate	Acidulant and buffer component
Sodium benzoate	Preservative
Strawberry flavor	Taste and odor masking

The combination of microcrystalline cellulose and carboxymethylcellulose sodium is commercially important. This excipient pair can create a structured suspension that limits sedimentation while allowing redispersion after shaking. It also increases viscosity, which can improve dose uniformity but may affect syringeability through oral or enteral dosing devices.

Glycerin supports mouthfeel and can reduce the perception of bitterness. Baclofen has a bitter pharmaceutical taste, making sweetener and flavor selection important. Sucralose and strawberry flavor provide a conventional pediatric-style taste profile, although Fleqsuvy is labeled for patients aged 12 years and older.[1]

Sodium benzoate gives the formulation a preservative system suitable for a multidose aqueous product. The citrate buffer controls pH and supports preservative performance, baclofen stability, and palatability.

What excipient strategy protects Fleqsuvy commercially?

The strongest commercial protection is likely to come from the interaction of excipients, concentration, packaging, and dosing performance rather than from any single inactive ingredient.

Suspension stability

A 5 mg/mL baclofen suspension must maintain dose uniformity throughout repeated use. Relevant performance attributes include:

• Sedimentation rate
• Ease of redispersion
• Delivered dose after storage
• Viscosity across temperature ranges
• Compatibility with oral syringes
• Compatibility with feeding tubes
• Resistance to caking
• Microbiological stability

A formulation that settles rapidly or forms a hard sediment creates a dosing risk. A formulation that is too viscous can produce incomplete syringe delivery and create tube-administration problems.

The microcrystalline cellulose-carboxymethylcellulose system provides a platform for tuning these properties. Changes in polymer grade, ratio, particle size, hydration time, and mixing process could produce meaningful differences in product performance even when the listed excipients remain familiar.

Taste masking

Baclofen is administered chronically, and taste can affect adherence. Sweetener concentration, flavor type, pH, glycerin content, and polymer level influence bitterness, aftertaste, and mouth coating.

Potential commercial improvements include:

• More effective bitterness suppression
• Lower aftertaste from high-intensity sweeteners
• Flavor systems designed for adolescent and adult use
• Sugar-free formulations
• Lower-viscosity products with less polymer mouthfeel
• Compatibility with patients receiving enteral nutrition

A taste-masking patent would be more valuable if it established a measurable performance advantage, such as improved palatability without increasing viscosity or compromising chemical stability.

Dosing-device compatibility

The commercial value of a liquid product depends partly on its delivery system. Relevant device claims may cover:

• Oral syringe graduation and accuracy
• Low-residual-volume syringes
• Bottle adapters
• Child-resistant closures
• Tube-administration systems
• Dose preparation and shaking instructions
• Packaging that limits sedimentation during use

Fleqsuvy’s concentration creates a smaller administration volume than low-strength baclofen liquids. That benefit can be strengthened through a device system that improves accuracy for doses such as 2.5 mL, 4 mL, or 5 mL.

Preservation and container closure

Sodium benzoate is a conventional preservative, but commercial opportunities may exist in preservative optimization. Key issues include preservative effectiveness after repeated opening, extractables and leachables from the bottle and closure, and stability under temperature excursions.

A preservative-free product could appeal to selected patients but would require an alternative microbiological control strategy, such as unit-dose packaging or a specialized dispensing system. That approach could increase manufacturing and packaging costs.

What patents protect Fleqsuvy?

Fleqsuvy does not have a new active ingredient. Baclofen has been marketed for decades, so composition-of-matter protection for the active ingredient is unavailable.

The relevant intellectual-property categories are:

1. Formulation patents covering the suspension vehicle, excipient ratios, pH, viscosity, particle size, or stability.
2. Method-of-use patents covering administration to patients unable to swallow tablets or use of a specified concentration.
3. Device patents covering dosing syringes, bottle adapters, or enteral delivery.
4. Manufacturing patents covering homogenization, wetting, dispersion, or control of suspended baclofen particles.
5. Packaging patents covering multidose storage, dosing, and tamper-resistant systems.

Publicly available FDA product information identifies Fleqsuvy as NDA 215831, approved on February 7, 2022.[1,2] FDA’s Orange Book is the controlling source for patents and regulatory exclusivity listed for an approved drug product.[3] No composition-of-matter patent should be expected for baclofen itself. Any meaningful patent estate would therefore depend on product-specific formulation, method, device, or manufacturing claims.

The commercial strength of those claims depends on whether a competing manufacturer can avoid the claimed excipient ranges while maintaining equivalent suspension performance. Broad claims covering common excipients can face validity and obviousness challenges. Narrow claims tied to demonstrated stability, redispersion, or dosing performance may be more defensible but easier to design around.

When does Fleqsuvy lose exclusivity?

Fleqsuvy received FDA approval on February 7, 2022. The product was developed through the 505(b)(2) pathway, which permits reliance in part on FDA findings for an earlier product while supporting differences in formulation, dosage form, or administration.[2]

A 505(b)(2) product may receive three years of FDA marketing exclusivity for new clinical investigations essential to approval. The relevant period for Fleqsuvy would generally run from the approval date if FDA granted that exclusivity, placing the potential endpoint in February 2025.[4]

That exclusivity does not create a long-term barrier to all baclofen products. It can restrict approval of certain follow-on applications that rely on the same FDA findings during the exclusivity period. It does not prevent all competing products, including potentially different formulations or products supported by an independent application.

Patent expiration depends on any patents listed in the Orange Book, including formulation, method-of-use, or device-related patents. The product’s commercial exposure therefore cannot be assessed from the baclofen molecule’s history alone.

Are there Paragraph IV challenges to Fleqsuvy?

A Paragraph IV challenge would be relevant if an ANDA applicant sought approval of a product referencing Fleqsuvy and certified that listed patents were invalid, unenforceable, or not infringed. The FDA Orange Book and FDA’s Paragraph IV litigation records are the key sources for identifying such challenges.[3,5]

The most likely target claims would cover:

• The 25 mg/5 mL suspension concentration
• The cellulose-based suspending system
• Preservative and pH ranges
• Taste-masking combinations
• Dosing-device configurations
• Stability or administration methods

Baclofen’s low-cost tablet market reduces the incentive to challenge a narrowly sized liquid market unless the challenger can secure meaningful pharmacy, institutional, pediatric, neurologic, or specialty-distribution volume.

What is the FDA regulatory status of Fleqsuvy?

Fleqsuvy is FDA-approved as an oral suspension for spasticity in patients 12 years of age and older. The product is supplied as a multidose liquid and requires shaking before administration.[1]

Key regulatory considerations include:

Regulatory issue	Fleqsuvy implication
FDA pathway	505(b)(2) NDA
NDA	215831
Approval date	February 7, 2022
Active ingredient	Baclofen
Strength	25 mg/5 mL
Dosage form	Oral suspension
Indication	Spasticity
Age group	Patients 12 years and older
Regulatory reference	FDA prescribing information and Orange Book

The product’s regulatory value is higher than the active ingredient’s value because the sponsor converted a long-established tablet drug into a commercially usable high-strength liquid. The approval package likely required evidence relating to formulation quality, stability, dose uniformity, microbiological control, and administration.

What commercial opportunities exist for Fleqsuvy excipients?

The best opportunities are in products that improve administration without triggering excessive development costs.

Higher-concentration baclofen liquids

A 25 mg/5 mL product already reduces volume relative to 5 mg/5 mL liquids. A future 50 mg/5 mL presentation could further reduce volume, but it would face greater risks involving solubility, suspension uniformity, taste, dose measurement, and prescribing errors.

A more realistic opportunity is a portfolio that combines:

• 25 mg/5 mL multidose suspension
• Unit-dose oral syringes
• Lower-strength liquid for titration
• Packaging for institutional use
• Feeding-tube-compatible administration

Improved palatability

A new flavor system or bitterness-suppression technology could support lifecycle management. The opportunity is strongest if the formulation reduces reliance on high sweetener levels or improves acceptance among adolescents and adults.

Excipient substitution

Potential substitutions include:

• Alternative suspending polymers
• Non-benzoate preservatives
• Natural or low-calorie sweeteners
• Improved flavor systems
• Lower-viscosity rheology modifiers
• Excipient systems compatible with enteral feeding tubes

Substitution creates a possible formulation patent position, but each change must preserve dose uniformity, stability, microbiological quality, and device compatibility.

Unit-dose and adherence packaging

Unit-dose packaging could reduce dosing errors and improve portability. It may also support hospital, rehabilitation, long-term-care, and specialty-pharmacy channels. The tradeoff is higher packaging cost and potentially greater distribution complexity.

Compounding replacement

Many baclofen liquid prescriptions may otherwise be handled through pharmacy compounding. A standardized FDA-approved product can compete by offering validated concentration, shelf-life data, labeling, and dosing instructions. This is a key commercial opportunity for Azurity and for specialty manufacturers entering the market.

How strong is the Fleqsuvy patent estate?

The estate is likely moderate to weak at the molecule level and potentially stronger at the formulation level.

IP category	Expected strength	Reason
Baclofen composition	Very low	Long-established generic active ingredient
Oral liquid dosage form	Low to moderate	Multiple liquid baclofen products and compounding precedent
25 mg/5 mL concentration	Moderate	Commercially useful, but potentially design-aroundable
Suspension excipient system	Moderate	Performance depends on specific ratios and process conditions
Taste masking	Moderate	Can be strengthened by comparative data
Dosing device	Moderate	Device claims can create incremental barriers
Manufacturing process	Moderate	Process claims may be difficult to detect and enforce
Clinical method of use	Low to moderate	Limited differentiation for a well-established indication

Patent strength will depend on claim breadth and clinical or product-performance evidence. A claim covering generic cellulose, glycerin, sucralose, citrate, and sodium benzoate without narrow functional limitations would face a substantial obviousness risk. Claims tied to unexpected stability, redispersion, dose accuracy, or taste performance are more commercially credible.

What generic entry risks exist for Fleqsuvy?

Generic entry risk is significant because the active ingredient is inexpensive and the principal differentiation is formulation-based. The main barriers are:

• Demonstrating equivalent dosage-form performance
• Matching suspension uniformity
• Establishing appropriate bioequivalence or comparative data
• Reproducing taste and viscosity acceptability
• Developing a compatible dosing device
• Meeting preservative-effectiveness requirements
• Securing access to specialty distribution channels

The most likely generic strategy is not an exact copy of every excipient. An applicant could use a different polymer system, flavor, sweetener, or preservative if it can meet FDA requirements and avoid valid patent claims.

Fleqsuvy may retain commercial protection after patent expiry through brand recognition, prescriber familiarity, patient continuity, and distribution relationships. Those protections are weaker in price-sensitive pharmacy channels than in specialty neurology, long-term care, and institutional settings.

Which companies compete with Fleqsuvy?

The competitive landscape includes generic baclofen tablet manufacturers, other liquid baclofen products, compounding pharmacies, and specialty pharmaceutical companies.

The most direct branded liquid competitor is Ozobax, a lower-strength baclofen oral solution. Generic tablets remain the largest structural competitor because they are inexpensive and widely available. Compounded liquids compete where prescribers require custom concentrations or pharmacies can provide local access.

Azurity’s commercial opportunity is strongest where tablets create a practical administration problem. This includes patients with dysphagia, patients receiving enteral nutrition, adolescents requiring liquid dosing, and patients who need small dose adjustments during titration.

What licensing and partnering opportunities exist?

Fleqsuvy-related licensing opportunities are more likely to concern platform technology than the baclofen molecule. Potential deal categories include:

• Suspending-polymer technology
• Taste-masking systems
• Low-volume oral dosing devices
• Enteral-tube delivery platforms
• Unit-dose packaging
• Specialty-pharmacy distribution
• Formulation manufacturing under contract
• Regional commercialization rights

A formulation-technology partner could improve lifecycle value by developing a lower-viscosity product, a pediatric-oriented flavor system, or a preservative-free unit-dose presentation. A device partner could add commercial differentiation without changing the approved active ingredient.

Manufacturing partnerships may focus on controlled polymer hydration, high-shear dispersion, microbial control, and bottle-filling operations. These process capabilities can be barriers when a product requires consistent suspension performance at commercial scale.

How does Fleqsuvy compare with Ozobax and generic baclofen?

Factor	Fleqsuvy	Ozobax	Generic tablets
Concentration	25 mg/5 mL	5 mg/5 mL	Fixed tablet strengths
Liquid volume	Lower	Higher	None
Dosing flexibility	High	High	Moderate
Swallowing burden	Low	Low	High
Excipient complexity	High	Moderate to high	Lower
Formulation patent opportunity	Meaningful	Meaningful	Limited
Price pressure	Moderate	Moderate	High
Compounding replacement value	High	High	Low
Tube-administration relevance	High	High	Limited

Fleqsuvy’s clearest advantage is reduced liquid volume. Ozobax may be more suitable for initial titration or patients requiring lower administration concentrations. Tablets remain preferable for patients who can swallow them and prioritize cost.

Key Takeaways

• Fleqsuvy is a 25 mg/5 mL baclofen oral suspension approved by FDA on February 7, 2022.
• Its commercial differentiation is based on liquid administration, high concentration, and reduced dosing volume.
• The formulation uses glycerin, microcrystalline cellulose and carboxymethylcellulose sodium, sucralose, citrate buffer components, sodium benzoate, and strawberry flavor.
• The strongest IP opportunities concern formulation performance, taste masking, dosing devices, packaging, and manufacturing processes.
• Baclofen has no meaningful new-molecule exclusivity because it is a long-established generic active ingredient.
• Generic entry risk is material because competitors can potentially design around individual excipients.
• The strongest commercial channels are specialty neurology, dysphagia care, enteral feeding, long-term care, hospitals, and replacement of compounded baclofen liquids.
• Lifecycle opportunities include unit-dose packaging, lower-volume presentations, improved palatability, preservative alternatives, and enteral-device integration.

FAQs About Fleqsuvy Excipient and Commercial Strategy

Is Fleqsuvy a solution or a suspension?

Fleqsuvy is an oral suspension. It contains suspended baclofen particles and requires shaking before administration to achieve dose uniformity.[1]

Why does Fleqsuvy use microcrystalline cellulose and carboxymethylcellulose sodium?

The excipient combination controls viscosity, limits sedimentation, and supports redispersion after shaking. It is central to the product’s physical stability and dose-delivery performance.

Can another company make a baclofen suspension with different excipients?

Yes. A competitor may develop a different excipient system if it meets FDA requirements for quality, stability, microbiological control, dose uniformity, and bioequivalence or other applicable approval standards.

Does Fleqsuvy have biosimilar risk?

No. Baclofen is a small-molecule drug, not a biologic. Fleqsuvy faces generic and 505(b)(2) competition rather than biosimilar competition.

What is the most valuable lifecycle extension for Fleqsuvy?

A lower-volume, easier-to-administer presentation with validated dosing-device compatibility would likely offer the clearest commercial benefit. Unit-dose packaging and improved taste masking are also practical lifecycle strategies.

References

1. U.S. Food and Drug Administration. (2022). Fleqsuvy (baclofen) oral suspension prescribing information.
2. U.S. Food and Drug Administration. (2022). Drugs@FDA: Fleqsuvy, NDA 215831.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2023). New drug product exclusivity.
5. U.S. Food and Drug Administration. (2024). Paragraph IV patent certifications and litigation information.